Application of pegylated recombinant humangranulocyte-colony stimulating factor in myelosuppression after chemotherapy for malignant tumor

  Objective  To investigate the effect of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) on myelosuppression after chemotherapy for malignant tumor.

  Methods  Totally 30 patients with systemic chemotherapy for malignant tumor were included in this study, and were given subcutaneous injection of PEG-rhG-CSF for a single dosage of 3 or 6 mg per time at 48 to 72 h after chemotherapy according to the body mass index, financial burden and severity of myelosuppression.

  Results  Out of 30 patients, 6 patients were given a dosage of 6 mg per time, 24 were given a dosage of 3 mg per time. None of patients developed 3 to 4 grade myelosuppression, but 6 cases occurred grade 1 granulocytopenia and 3 with grade 2 granulocytopenia.

  Conclusion  The subcutaneous injection of PEG-rhG-CSF can effectively prevent the granulocytopenia induced by chemotherapy. The dosage of PEG-rhG-CSF should be adjusted according to the body mass index, financial burden and severity of myelosuppression.